ref_name,rx_name,control_iso_name,iso_name,section,assay_name,potency_type,fold_cmp,fold,resistance_level,ineffective,cumulative_count,date_added
FDA21c,CIL,Wuhan-Hu-1,S:346I,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,>,200,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:444E,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,>,200,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:444Q,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,>,200,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:444R,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,>,200,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:445A,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,36,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:446V,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,4.2,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:450K,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,9.1,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,S:452R,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,5.8,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:414R,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,4.6,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:455F,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,3.6,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:476S,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,3.3,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:484D,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,7.1,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:484K,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,9.1,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:484Q,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,3,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:486S,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,>,600,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:486V,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,135,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:493K,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,2.8,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:493R,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,7.9,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:990A,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,6.1,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,S:1009I,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,8.2,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:484K,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,3.9,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:493R,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,3.4,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:990A,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,5.7,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:1009I,"Feb 2022, Page 16, Antiviral resistance paragraph 3",Pseudovirus,IC50,=,4.5,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,B.1.621 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 4",Pseudovirus,IC50,=,21,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,B.1.1.7 Spike+S:484K,"Feb 2022, Page 17, Antiviral resistance paragraph 4",Pseudovirus,IC50,=,18.5,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,B.1.351 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 4",Pseudovirus,IC50,=,9.3,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,P.2 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 4",Pseudovirus,IC50,=,7.3,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,BA.1 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 5",Pseudovirus,IC50,>,1000,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,BA.1.1 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 5",Pseudovirus,IC50,=,460,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,BA.1 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 5",Pseudovirus,IC50,>,1000,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,BA.1.1 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 5",Pseudovirus,IC50,>,500,NULL,NULL,1,2022-03-17
FDA21c,TIX,Wuhan-Hu-1,BA.2 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 5",Pseudovirus,IC50,>,1000,NULL,NULL,1,2022-03-17
FDA21c,CIL,Wuhan-Hu-1,BA.2 Spike,"Feb 2022, Page 17, Antiviral resistance paragraph 5",Pseudovirus,IC50,=,1.9,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.1.7 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,2.9,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.351 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,2.4,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,P.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,1.2,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.617.2 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,1.2,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.617.2 Spike:+417N,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,BA.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 7",Pseudovirus,IC50,=,157.5,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,BA.1.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 7",Pseudovirus,IC50,=,424,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,BA.2 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 7",Pseudovirus,IC50,=,3.2,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.525 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,3.1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.526/E484K Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,1.9,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.617.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,2,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,C.37 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,0.7,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.621 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,7.5,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.427/9 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,2.2,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:152L+484K+614G+769V,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,3.5,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.1.519 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,1.4,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:12F+69del+70del+152R+346S+452R+614G+677H+899S,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,2.3,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,S:214ins+414K+450K+614G+716I,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,0.8,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.619.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,3.3,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,P.2 Spike,"Feb 2022, Table 6",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.616 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,0.5,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,A.23.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,0.4,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,A.27 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,0.8,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,AV.1 Spike,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 6",Pseudovirus,IC50,=,5.9,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.1.7 full genome,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.351 full genome,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,P.1 full genome,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.617.2 full genome,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.617.2 full genome + S:417N,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,Omicron/BA.1 full genome,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 7",Virus isolate,IC50,=,21,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,Omicron/BA.1.1 full genome,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 7",Virus isolate,IC50,=,176,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,Omicron/BA.2 full genome,"Feb 2022, Table 6, Page 17, Antiviral resistance paragraph 7",Virus isolate,IC50,=,5.4,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.526 full genome/E484K,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.617.1 full genome,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
FDA21c,CIL+TIX,Wuhan-Hu-1,B.1.427 full genome,"Feb 2022, Table 6",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-17
